A detailed history of Federated Hermes, Inc. transactions in Biogen Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 102,584 shares of BIIB stock, worth $15.3 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
102,584
Previous 102,942 0.35%
Holding current value
$15.3 Million
Previous $23.9 Million 16.68%
% of portfolio
0.05%
Previous 0.06%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$189.07 - $236.8 $67,687 - $84,774
-358 Reduced 0.35%
102,584 $19.9 Million
Q2 2024

Aug 08, 2024

BUY
$190.52 - $236.72 $41,533 - $51,604
218 Added 0.21%
102,942 $23.9 Million
Q1 2024

May 14, 2024

BUY
$212.02 - $267.71 $546,163 - $689,620
2,576 Added 2.57%
102,724 $22.2 Million
Q4 2023

Jan 31, 2024

SELL
$222.59 - $267.94 $961,588 - $1.16 Million
-4,320 Reduced 4.14%
100,148 $25.9 Million
Q3 2023

Nov 13, 2023

BUY
$253.3 - $285.89 $11.2 Million - $12.7 Million
44,328 Added 73.71%
104,468 $26.8 Million
Q2 2023

Aug 14, 2023

SELL
$275.25 - $318.06 $751,707 - $868,621
-2,731 Reduced 4.34%
60,140 $17.1 Million
Q1 2023

May 08, 2023

BUY
$256.56 - $292.34 $64,140 - $73,085
250 Added 0.4%
62,871 $17.5 Million
Q4 2022

Feb 13, 2023

SELL
$252.44 - $306.72 $18.2 Million - $22.1 Million
-72,028 Reduced 53.49%
62,621 $17.3 Million
Q3 2022

Nov 14, 2022

SELL
$194.69 - $268.46 $34.5 Million - $47.6 Million
-177,323 Reduced 56.84%
134,649 $36 Million
Q2 2022

Aug 15, 2022

BUY
$187.54 - $223.02 $17.3 Million - $20.5 Million
91,985 Added 41.81%
311,972 $63.6 Million
Q1 2022

May 13, 2022

BUY
$193.77 - $244.14 $29.2 Million - $36.8 Million
150,537 Added 216.76%
219,987 $46.3 Million
Q4 2021

Feb 14, 2022

BUY
$223.92 - $287.77 $14.3 Million - $18.4 Million
64,015 Added 1177.83%
69,450 $16.7 Million
Q3 2021

Nov 15, 2021

SELL
$282.99 - $369.05 $43,014 - $56,095
-152 Reduced 2.72%
5,435 $1.54 Million
Q2 2021

Aug 16, 2021

SELL
$259.0 - $414.71 $464,128 - $743,160
-1,792 Reduced 24.29%
5,587 $1.94 Million
Q1 2021

May 13, 2021

SELL
$242.95 - $284.63 $14.9 Million - $17.4 Million
-61,203 Reduced 89.24%
7,379 $2.06 Million
Q4 2020

Feb 12, 2021

SELL
$236.26 - $355.63 $10.2 Million - $15.3 Million
-43,012 Reduced 38.54%
68,582 $16.8 Million
Q3 2020

Nov 12, 2020

SELL
$264.77 - $305.71 $24.3 Million - $28 Million
-91,748 Reduced 45.12%
111,594 $31.7 Million
Q2 2020

Aug 13, 2020

BUY
$258.66 - $342.55 $15.2 Million - $20.1 Million
58,606 Added 40.49%
203,342 $54.4 Million
Q1 2020

May 13, 2020

SELL
$268.85 - $341.04 $3.8 Million - $4.82 Million
-14,130 Reduced 8.89%
144,736 $45.8 Million
Q4 2019

Feb 14, 2020

SELL
$220.06 - $304.07 $35.6 Million - $49.2 Million
-161,853 Reduced 50.47%
158,866 $47.1 Million
Q3 2019

Nov 14, 2019

BUY
$217.44 - $243.88 $11.9 Million - $13.4 Million
54,821 Added 20.62%
320,719 $74.7 Million
Q2 2019

Aug 14, 2019

BUY
$219.29 - $241.72 $11.3 Million - $12.4 Million
51,424 Added 23.98%
265,898 $62.2 Million
Q1 2019

May 10, 2019

SELL
$216.71 - $338.96 $6.91 Million - $10.8 Million
-31,893 Reduced 12.95%
214,474 $50.7 Million
Q4 2018

Feb 13, 2019

BUY
$278.5 - $352.75 $5.92 Million - $7.5 Million
21,274 Added 9.45%
246,367 $74.1 Million
Q3 2018

Nov 13, 2018

BUY
$293.51 - $383.83 $65 Million - $85 Million
221,374 Added 5952.51%
225,093 $79.5 Million
Q2 2018

Aug 10, 2018

SELL
$257.52 - $306.91 $7,725 - $9,207
-30 Reduced 0.8%
3,719 $1.08 Million
Q1 2018

May 09, 2018

SELL
$260.13 - $367.91 $15,087 - $21,338
-58 Reduced 1.52%
3,749 $1.03 Million
Q4 2017

Feb 14, 2018

BUY
$307.64 - $344.58 $31,379 - $35,147
102 Added 2.75%
3,807 $0
Q3 2017

Nov 13, 2017

BUY
$281.15 - $329.69 $1.04 Million - $1.22 Million
3,705
3,705 $1.16 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.5B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.